CAR-T Characterization Panel
Helping Your Research
The nCounter CAR-T Characterization Panel was created in collaboration with experts in CAR-T therapy to facilitate the development of robust product release assays. Confidently profile CAR-T products for research and manufacturing applications with an automated, and reproducible assay. Ideally suited for new CAR-T development and QC, the CAR-T Characterization Gene Expression Panel can help streamline the CAR-T manufacturing workflow and potentially reduce vein to vein time. This panel can measure eight essential components of CAR-T biology with 780 human genes.
Empower your knowledge of CAR-T with the most up-to-date biology developed with experts in the field.
- Optimize CAR-T method development
- Create manufacturing acceptance criteria
- Measure metabolic fitness and persistence
- Monitor post-infusion exhaustion and toxicity
How It Works
CAR-T Therapy Workflow
Understanding each step of the CAR-T workflow is critical to ensuring quality and efficacy of the final CAR-T product. The nCounter CAR-T Characterization Panel can be used throughout development and manufacturing as a standardized panel of genes for optimizing methods, developing manufacturing acceptance criteria as well as understanding the host influences beyond manufacturing.
In addition to the standard nSolver™ Analysis, genes included in the CAR-T Characterization panel are organized and linked to various advanced analysis modules to allow for efficient exploration of the eight essential aspects of CAR-T biology.
Advanced Analysis Modules available for CAR-T Characterization:
Gene Set Analysis
Built-in Compatibility for Panel Plus and Protein Analysis
TCR Diversity Score (inquire)
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel proFind Your Panel
NanoString is excited to be working with Servier (as project leader), Bayer, Janssen, and Takeda as partners with the Innovative Medicines Initiative (IMI) Consortium in the European Union to develop gold standard analytical methods to use throughout development, manufacturing, and delivery of CAR-T cell therapies. The IMI is the largest public-private partnership in the world dedicated to health research.
Tracking immunodynamics by identification of S-G2/M-phase T cells in human peripheral blood.
The ready availability of human blood makes it the first choice for immuno-monitoring. However, this has been largely confined to static metrics, particularly resting T cell phenotypes.
Impact of checkpoint blockade on cancer vaccine-activated CD8+ T cell responses.
Immune and molecular profiling of CD8 T cells of patients receiving DC vaccines expressing three full-length melanoma antigens (MAs) was performed. Antigen expression levels in DCs had no significant impact on T cell or clinical responses.
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Background: Although immune checkpoint inhibitors have revolutionized cancer treatment, clinical benefit with this class of agents has been limited to a subset of patients. Hence, more effective means to target tumor cells that express immune checkpoint molecules should be developed.